ALSO NOTED: YM cuts losses;French launch vaccines probe; diabetes foundation contributes research funds; and much more...

> YM Biosciences managed to halve its pre-tax loss for the first half by cutting expenses. Release

> French authorities are investigating GlaxoSmithKline and Sanofi Pasteur over an anti-hepatitis B vaccination campaign in the 1990s. At issue is whether the companies fully disclosed the shot's potential side effects. Report

> The Juvenile Diabetes Research Foundation is giving Plureon $500,000 over two year to research new treatments for type 1 diabetes. Report

> A new blend of a genetically modified chimp adenovirus and a malaria gene is proving promising as a potential vaccine against malaria. Report

> When the American College of Cardiology sent out its annual meeting agenda, the controversial ENHANCE study wasn't listed as a highlighted presentation. Report

> Manhattan Pharmaceuticals has entered into a joint venture agreement with Nordic Biotech Advisors ApS (Nordic) to develop and commercialize Hedrin, the company's novel, non-insecticide treatment for head lice. Release

> Twenty-three people have died after being injected with colchicine, a gout drug that's FDA-approved only for oral use. Report

> A few hours of extreme drowsiness is not a bad trade-off for schizophrenia patients who have problems sticking to their medication. So said an FDA advisory committee yesterday in backing approval of Eli Lilly's new long-acting, injectable form of Zyprexa. Report

> Plummeting Avandia sales have taken a toll on GlaxoSmithKline's bottom line. Report

And Finally… Researchers can now use a transparent zebrafish to help them advance their understanding of disease. Release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.